Case Study: Acuitas Therapeutics strengthens its scientific authority and media visibility with HDMZ

Acuitas Therapeutics amplifies its scientific voice with HDMZ across 2 approved LNP products

The customer, Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery technology, faced the challenge of amplifying its story beyond its role in COVID-19 vaccines to showcase its broader expertise. They engaged the vendor HDMZ to help reshape its public narrative and establish its authoritative voice in the scientific community.

HDMZ implemented a focused PR strategy to highlight Acuitas's novel scientific approaches and key achievements, such as its work on extrahepatic delivery and a landmark CRISPR therapy trial. This solution successfully generated broad media coverage in top-tier outlets, strengthening Acuitas's position as a scientific authority and showcasing its crucial contributions to a wide array of partner programs.

Acuitas Therapeutics